Board summary
Key figures
40,645
Registered population
63.4% aged 18–64
16.6%
Aged 65+
ICB 14.9% · England 17.9%
23.8%
In IMD quintile 1
ICB 40.7% · England 21.0%
~8,846
Core20 residents (est.)
Resident basis; registered basis ~9,249 · see page 3
6,460
Hypertension register
+3.58% in 3 yrs · England +5.60%
502
SMI register
15% of Stockport (LAD)'s
1,012
COPD register
Reviews -8.13% in 3 yrs
Forecast to 2030
6,999
Hypertension patients, 2030
+539 on today
75.7%
QRISK ≥20% on statins, 2030
+2.35pp over 3 yrs
4.7%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma review rate fell over three years.
About 966 asthma patients lack a recorded review; completion is 67.5% (England 65.7%) after a 5.0% three-year fall (England +4.4%), which may reflect recall.
Lipid therapy for high QRISK exceeds England.
Lipid-lowering therapy reaches 70.8% of patients with QRISK ≥ 20% (England 63.6%, Stockport (LAD) 64.8%), although three-year growth was +3.4% against England's +6.2%.
Population, age and ethnicity
Older adults comprise 16.6% of patients, trailing Stockport's 19.7% while working ages predominate
Across 40,645 registered patients, 16.6% (6,743) are aged 65+, below Stockport (LAD) at 19.7% and England at 17.9%, but above NHS Greater Manchester Integrated Care Board at 14.9%. Working-age adults aged 18-64 comprise 63.4% (25,749), above Stockport (LAD) at 60.6%, matching the ICB at 63.3%, and above England at 62.7%. Children aged 0-17 represent 20.1% (8,153; Stockport (LAD) 19.7%, ICB 21.8%, England 19.6%). Catchment services include 16 care homes with 716 beds. Roma residents comprise 0.1% and Gypsy or Irish Traveller 0.0%. Projected list growth to 2030 is 0.5% (Stockport (LAD) 1.1%, ICB 1.6%, England 2.3%; unverified methodology).
Age profile
65+: ICB 14.9%, England 17.9%
Older people · falls rows are Stockport (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Stockport LA) | 2,072 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 80.9% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 56.9% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Stockport LA) | 919 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Stockport LA) | 23.7 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 patients comprise 23.8% of the list, spanning 32.0 percentage points across practices
Core20 patients make up 23.8% of the PCN list, above Stockport (LAD) at 16.1% and England at 21.0%, but below NHS Greater Manchester Integrated Care Board at 40.7%, representing about 8,800 estimated residents. Deprivation spans a 32.0 pp range across practices: Adshall Road Medical Prac has the highest share at 32.0% (1,543 estimated patients), whereas Stockport Medical Group holds the largest volume at 5,356 estimated patients (30.0%). The modelled weighted practice share is 22.8%.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
502
SMI register
1.21% recorded prevalence
263
Learning disability register
0.63% recorded prevalence
16
Care homes, 716 beds
In the PCN catchment
9.5%
Provide unpaid care
Stockport (LAD), Census 2021
The PCN records 502 patients on the severe mental illness register (1.2% prevalence, compared with 1.0% in Stockport (LAD), 1.1% in NHS Greater Manchester Integrated Care Board, and 1.0% in England). The learning disability register includes 263 patients (0.6% prevalence, matching Stockport (LAD), the ICB, and England at 0.6%). Higher recorded severe mental illness prevalence may increase routine physical health review demand across member practices.
Severe mental illness: physical health checks
SMI prevalence is 1.2% (England 1.0%). Recorded BMI checks reach 79.5% (England 82.1%, Stockport (LAD) 84.0%), with three-year progress of +1.7 pp (2023 to 2025) lagging England (+5.1 pp).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
6,460
Hypertension register
+3.58%
Register growth, 3 yrs
Stockport (LAD) +4.99% · England +5.60%
+0.12pp
BP control, under 80
≤140/90 · −0.70pp aged 80+
+539
More patients by 2030
Forecast 6,999 (16.67%)
Hypertension case-finding and control
Hypertension prevalence is 15.5% (6,460 patients), against 16.2% in Stockport (LAD), 14.4% in NHS Greater Manchester Integrated Care Board, and 15.2% in England. Recent blood pressure monitoring reaches 91.2% (England 90.0%), but three-year register growth of +3.6% (2023 to 2025) trails England (+5.6%) and the borough (+5.0%). Blood pressure control under age 80 stands at 69.7% (England 67.8%), though three-year progress (+0.2%, +0.1 pp) lags England (+3.2%, +2.1 pp) and the ICB (+3.6%, +2.4 pp). Caritas General Practice Partnership records 66.5% control under age 80. Plateauing blood pressure control despite high monitoring suggests an opportunity to standardise treatment titration across practices before clinical outcomes decline.
Lipids and statins
Lipid-lowering therapy reaches 70.8% of patients with QRISK ≥ 20%, exceeding England (63.6%) and Stockport (LAD) (64.8%). Conversely, statin coverage for diabetes without cardiovascular disease fell 2.6% over three years (2023 to 2025; England +2.1%) to 72.9% (England 73.2%). Lower primary-prevention statin use than England implies an opportunity to prioritise cardiovascular prevention in unreviewed diabetes.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 95,915 | £2.00 | £1.94 | £1.86 | £191,830 |
| Cardiovascular (all), 2025 | 130,275 | £2.70 | £3.15 | £3.33 | £351,742 |
In 2026, the PCN prescribed 95,915 lipid-regulating items at £2.00 per item, above England (£1.86), Stockport (LAD) (£1.99), and NHS Greater Manchester Integrated Care Board (£1.94). Across 95,915 items, this is £13,428 more than at England's unit cost. This unit-cost indicator does not establish efficiency or case-mix differences; formulary audit would test prescribing variation.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−5.01%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−3.65%
Asthma prevalence, PCN 3-yr % change
Current review completion exceeds England for COPD at 80.0% (England 76.4%) and asthma at 67.5% (England 65.7%). Over three years (2023 to 2025), reviews fell 8.1% for COPD (England +2.8%) and 5.0% for asthma (England +4.4%), leaving about 970 asthma patients without a recorded review. Asthma prescribing reaches 1,958 items per 1,000 aged 5-19 (England 1,488). Declining reviews alongside higher youth prescribing could indicate unreviewed maintenance; clinical recall audit would test this.
Cancer register and children's immunisation
Cancer register prevalence is 3.8% (1,592 patients, matching England at 3.8%). In Q1 2025/26, 6-in-1 coverage at 12 months reached 96.5%, meeting the 95.0% target. At age 5, MMR dose 1 reached 95.4%, but MMR dose 2 was 91.7% (below target by 3.3 pp) and 4-in-1 booster coverage was 86.2% (below target by 8.8 pp).
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
In 2022, 55.6% of staged cancers in NHS Greater Manchester ICB were diagnosed at stage 1 or 2 (6,491 of 11,679), matching England (55.3%) but 19.4 pp below the 75.0% 2028 ambition. Reaching it requires about 2,270 extra early diagnoses annually; early-stage share rose 3.1 pp from 2013 to 2022. Known-stage completeness was 70.8% (11,679 of 16,492). For the PCN (1,592 cancer patients), cervical screening is 75.4% (Stockport 75.9%), trailing at Caritas General Practice Partnership (74.4%) and Stockport Medical Group (72.2%). System staging is ICB level, not PCN performance. Screening variation across practices highlights where proactive recall could support earlier cancer presentation.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026, Stockport NHS Foundation Trust achieved 74.7% on the 62-day cancer standard, below the 85.0% standard by 10.3 pp (Manchester University 72.8%, Tameside and Glossop 76.8%, ICB 75.7%, England 71.2%). The trust met the 28-day faster diagnosis standard at 83.2% (standard 75.0%; ICB 79.5%, England 79.3%). For diagnostics, 14.1% waited 6+ weeks at Stockport NHS Foundation Trust (Manchester University 9.0%, Tameside and Glossop 0.8%, England 23.1%), with delays in audiology (67.7%) and urodynamics (50.9%). Trust figures reflect provider activity, not PCN performance.
| Pathways within standard (%) | Stockport | Manchester | Tameside and Glossop Integrated Care | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 83.21 | 80.06 | 82.48 | 79.53 | 79.32 |
| 31-day treatment (96%) | 97.39 | 92.54 | 96.25 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 74.67 | 72.85 | 76.77 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Stockport | Manchester | Tameside and Glossop Integrated Care | England |
|---|---|---|---|---|
| MRI | 1.41 | 11.68 | 0.00 | 21.40 |
| CT | 2.93 | 14.66 | 0.18 | 9.92 |
| Echocardiography | 17.46 | 4.91 | 0.00 | 28.48 |
| Colonoscopy | 5.53 | 4.51 | 1.51 | 30.83 |
| Gastroscopy | 5.31 | 29.35 | 5.45 | 29.02 |
| All 15 DM01 tests | 14.08 | 8.98 | 0.80 | 23.14 |
| Community services activity | Stockport residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 57,085 | 573,310 |
| Referrals | 10,690 | 94,470 |
| Patients with a contact | 16,950 | 183,535 |
Community services (residents of Stockport), Jun 2026 (provisional). In Jun 2026, provisional Community Services Data Set records show that 60.6% of community contacts among Stockport local authority residents were with adults aged 65 and over (34,585 of 57,085 contacts). While this demonstrates that community activity is predominantly delivered to older residents across the borough, these figures reflect resident local authority contacts rather than PCN-level provision and do not capture provider attribution.
Practice variation and patient experience
Phone access spans 31.0 pp and vaccination achievement 71.2 pp across practices
In 2025/26, QOF overall achievement ranged from 91.8% at Adshall Road Medical Prac to 96.2% at Stockport Medical Group (England 92.5%). Vaccination and immunisation achievement diverged by 71.2 pp, from 28.1% at Adshall Road Medical Prac to 99.3% at Bracondale Medical Centre (England 55.2%), highlighting a wide achievement span across member practices.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Bracondale | 102 | 0.0 | 79.9% | 70.8% | 93.7% |
| Adshall Road | 119 | 32.0 | 77.1% | 70.7% | 91.8% |
| Caritas General | 117 | 19.3 | 63.9% | 70.8% | 89.0% |
| Stockport Medical | 113 | 30.0 | 48.9% | 75.0% | 75.7% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Seventeen of 25 measures trail England over three years, led by respiratory reviews
Across 25 compared indicators, 17 trail England's three-year change (2023 to 2025). The widest relative lags appear in annual COPD reviews, falling 8.1% (England +2.8%, a 10.88-point gap), and annual asthma reviews, down 5.0% (England +4.4%, a 9.45-point gap). Statin treatment in diabetes without CVD fell 2.6% (England +2.1%), while HbA1c control without frailty gained 1.3% (England +4.4%). Conversely, alcohol recording in psychosis rose 12.0 pp (England +5.4 pp), breast screening coverage increased 14.2% (England +8.4%), and cervical screening gained 1.9% (England -1.0%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
COPD reviews
Asthma reviews
COPD register
Diabetes statin (no CVD)
Asthma register
Alcohol record (psychosis)
Breast screening (53-70)
Cervical screening
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Stockport (LAD) | Asset | PCN | Stockport (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 16 (716 beds) | n/a | Schools (catchment) | 72 | n/a |
| Children's centres | 1 | 2 | Places of worship | 47 | 135 |
| Libraries | 3 | 12 | Food banks (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 17 | 61 | Primary academies | 6 | 23 |
| Special schools | 2 | 4 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma review and prescribing recall
Asthma reviews reach 67.5% (England 65.7%, Stockport (LAD) 63.4%), but fell 5.0% (by 3.6 pp) from 2023 to 2025 while England rose +4.4% (+2.8 pp), leaving 966 of 2,973 patients unreviewed. For discussion, practices could run a recall audit combining annual asthma reviews with inhaler prescribing checks. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Hypertension under-80 treatment titration recall
Blood pressure control under 80 across 6,460 patients is 69.7% (England 67.8%, Stockport (LAD) 70.8%; Caritas General Practice Partnership 66.5%), with 2023 to 2025 change at +0.2% (+0.1 pp) versus England's +3.2% (+2.1 pp). For discussion, the PCN could consider pharmacist-led recall and medicines titration for patients above threshold. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Two-track Core20 access and telephony review
In Jan-Apr 2026, easy phone contact was 48.9% at Stockport Medical Group (England 56.9%; 5,356 estimated Core20, 30.0%) versus 79.9% at Bracondale Medical Centre (31.0 pp range); Adshall Road Medical Prac has 32.0% Core20 (1,543 estimated). Moderate effort to run.
Evidence base: the share of patients in the most deprived quintile is the Core20 targeting measure used to weight inequalities funding, outreach and prevention capacity, and the gradient every clinical indicator should be read against.
Policy anchor: Core20PLUS5 (Core20 = the most deprived 20% by IMD); 10 Year Health Plan, with widening inequalities the equity test of reform.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Care home clinical review coordination (p2) | Count of Care Homes in PCN catchment | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework: revenue finance and contracting guidance 2026 | PCN |
| Two-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical health recall (p4) | SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension control audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster catch-up audit (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Screening uptake and early presentation (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Practice telephony and triage review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma review and prescribing recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Asthma management items prescribed per 1000 5-19 Population | Core20PLUS5 respiratory | PCN |
| Option 2 · Hypertension under-80 treatment titration recall (p12) | Hypertension register · Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) · Hypertension patients with a recent BP reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN & Practice |
| Option 3 · Two-track Core20 access and telephony review (p12) | Core20 cohort (IMD quintile 1) · GPPS easy to contact the practice by phone · GPPS easy to contact the practice using its website | Core20PLUS5 · 10YHP equity test · 10YHP, hospital to community | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
